

# NEWSFLASH



## CerebroVascular Disease-Cognition phase-2 trial in non-lacunar ischaemic stroke with cerebral small vessel disease

**CVD-Cog has secured funding from the Alzheimer's Society.**

**We are now in the final stages of preparation, with ethics and regulatory submissions underway and on track for approval.**

We aim to start site set-up in October 2025 and open recruitment in December 2025. Thank you for all expressions of interest so far - we look forward to working with you as we move closer to approval.

### Trial Summary

**PURPOSE:** The purpose of CVD-Cog is to investigate whether isosorbide mononitrate and/or cilostazol are effective in treating cerebral small vessel disease (cSVD) in patients who have had a non-lacunar ischaemic stroke or TIA.

**DESIGN:** Prospective randomised open-label blinded-endpoint partial-factorial trial.

**PARTICIPANTS:** 400 participants will be recruited from 25 sites. Participants must be 7 days from diagnosis with a non-lacunar ischaemic stroke or TIA and have cSVD on their CT and/or MR brain scan.

**INTERVENTION:** Participants not taking an oral anti-coagulant will be assigned at random to one of four treatment groups:

1. Isosorbide mononitrate only.
2. Cilostazol only.
3. Both cilostazol and isosorbide mononitrate.
4. Neither cilostazol nor isosorbide mononitrate.

Participants on an oral anti-coagulant will be randomised to isosorbide mononitrate or no isosorbide mononitrate.

**FOLLOW UP:** Participants will be treated and followed for 6 months. The trial is funded for 3 years.

Follow our progress on **X** @CVDCog

**If you have any questions, please get in touch:**



**CVD-Cog@nottingham.ac.uk**